Dianthus Therapeutics | 8-K:重大事件
Dianthus Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-Avidity Partners Management LP(9.9%),Avidity Partners Management (GP) LLC(9.9%)等
Dianthus Therapeutics | SC 13G:超过5%持股股东披露文件-TCG Crossover GP II, LLC(5.1%),TCG Crossover Fund II, L.P.(5.1%)等
Dianthus Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Venrock Healthcare Capital Partners III, L.P.(5.9%),VHCP Co-Investment Holdings III, LLC(5.9%)等
Dianthus Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-5AM Ventures VII, L.P.(3.5%),5AM Partners VII, LLC(3.5%)等
Dianthus Therapeutics | SC 13G:超过5%持股股东披露文件-BlackRock, Inc.(5.6%)
Dianthus Therapeutics | 8-K:重大事件
Dianthus Therapeutics | 10-Q:2024财年三季报
Dianthus Therapeutics | SC 13G:超过5%持股股东披露文件-BlackRock, Inc.(5.6%)
Dianthus Therapeutics | RW:注册提款请求
Dianthus Therapeutics | 424B5:募资说明书
Dianthus Therapeutics | SC 13G:超过5%持股股东披露文件-Octagon Capital Advisors LP(6.0%),Ting Jia(6.0%)等
Dianthus Therapeutics | 424B3:募资说明书
Dianthus Therapeutics | EFFECT:其他
Dianthus Therapeutics | EFFECT:其他
Dianthus Therapeutics | CORRESP:信函
Dianthus Therapeutics | CORRESP:信函
Dianthus Therapeutics | UPLOAD:其他
Dianthus Therapeutics | UPLOAD:其他
Dianthus Therapeutics | 4:持股变动声明-董事 Fairmount Funds Management LLC